These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? Esteva FJ; Miller KD; Teicher BA Am Soc Clin Oncol Educ Book; 2015; ():e117-25. PubMed ID: 25993162 [TBL] [Abstract][Full Text] [Related]
4. Antibody drug conjugates. Teicher BA Curr Opin Oncol; 2014 Sep; 26(5):476-83. PubMed ID: 25024051 [TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Antibody-Drug Conjugates in Cancer. Wolska-Washer A; Robak T Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747 [TBL] [Abstract][Full Text] [Related]
7. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Senter PD; Springer CJ Adv Drug Deliv Rev; 2001 Dec; 53(3):247-64. PubMed ID: 11744170 [TBL] [Abstract][Full Text] [Related]
8. Antibody-drug Conjugate Targets, Drugs, and Linkers. Teicher BA; Morris J Curr Cancer Drug Targets; 2022; 22(6):463-529. PubMed ID: 35209819 [TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Goldmacher VS; Kovtun YV Ther Deliv; 2011 Mar; 2(3):397-416. PubMed ID: 22834009 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of precision antibody conjugates using proximity-induced chemistry. Cao YJ; Yu C; Wu KL; Wang X; Liu D; Tian Z; Zhao L; Qi X; Loredo A; Chung A; Xiao H Theranostics; 2021; 11(18):9107-9117. PubMed ID: 34522229 [No Abstract] [Full Text] [Related]
11. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Liu SN; Li C Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763 [TBL] [Abstract][Full Text] [Related]
13. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Jackson D; Stover D Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341 [TBL] [Abstract][Full Text] [Related]
15. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates. Huennekens FM Adv Enzyme Regul; 1997; 37():77-92. PubMed ID: 9381987 [TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy. Hasan M; Alam S; Poddar SK Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930 [TBL] [Abstract][Full Text] [Related]
17. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Dosio F; Brusa P; Cattel L Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in tumor-targeting anticancer drug conjugates. Jaracz S; Chen J; Kuznetsova LV; Ojima I Bioorg Med Chem; 2005 Sep; 13(17):5043-54. PubMed ID: 15955702 [TBL] [Abstract][Full Text] [Related]
19. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Edupuganti VVSR; Tyndall JDATDA; Gamble AB Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624 [TBL] [Abstract][Full Text] [Related]
20. [Targeted cytotoxic drugs emerging for cancer therapy]. Junttila TT; Tanner M; Isola J Duodecim; 2011; 127(4):343-9. PubMed ID: 21442854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]